Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
About Chromadex Corp
Chromadex Corp (CDXC) is a globally recognized integrated nutraceutical and bioscience company committed to improving the quality of life through advanced research on healthy aging. The company is deeply invested in understanding the mechanisms by which cellular processes, particularly those involving nicotinamide adenine dinucleotide (NAD+), impact the aging process. With a core focus on innovative science, Chromadex has developed a multifaceted business model that spans from research breakthroughs to commercially available consumer products, ensuring that its scientific discoveries translate into meaningful daily benefits.
Business Model and Core Segments
Chromadex’s operational framework is built on three primary segments that work in unison to deliver high-quality, science-based nutraceutical innovations:
- Consumer Products: This segment is primarily responsible for marketing and distributing products directly to the consumer market. Its portfolio features formulations designed to support healthy aging by leveraging proprietary, scientifically validated ingredients. The company’s flagship product, built around the NAD+ precursor nicotinamide riboside (NR), exemplifies its commitment to translating rigorous research into everyday solutions.
- Ingredients Segment: Focused on the development and licensing of novel ingredients, this segment utilizes high-caliber scientific research to create bioactive compounds. These innovations are targeted for use in various applications, ranging from dietary supplements to functional foods, ensuring that the expertise of Chromadex is shared widely across the industry.
- Analytical Reference Standards and Services: This area underpins the rigorous quality control and analytical validation processes that are crucial to research and product development. By offering specialized standards and services, Chromadex supports both internal development and external quality assurance needs in a scientifically robust manner.
Research and Innovation
At the heart of Chromadex’s operations is a steadfast commitment to research and development. The company partners with leading universities and research institutions worldwide to explore the potential of critical biochemical pathways related to aging. This collaborative approach not only strengthens its research capabilities but also ensures that the ingredients developed are based on solid scientific evidence. The integration of cutting-edge bioscience and precise analytical methodologies solidifies its position as a trusted name in the nutraceutical industry.
Market Position and Competitive Differentiation
Chromadex distinguishes itself by focusing on the intersection of scientific innovation and consumer wellness. Its emphasis on NAD+ research, an area that has increasingly become synonymous with the study of aging and cellular health, sets it apart in a competitive landscape that includes various bioscience and nutraceutical companies. The company’s multidimensional approach, which bridges direct consumer engagement with deep scientific inquiry, provides a unique value proposition that caters both to health-conscious individuals and to industry partners seeking high-quality, science-backed ingredients.
Commitment to Transparency and Quality
Transparency in research and product development is a core tenet of Chromadex’s philosophy. Every stage of its process—from initial scientific exploration to the final formulation—undergoes rigorous analytical review and quality control. This disciplined approach reassures consumers and industry collaborators alike, fostering trust and establishing Chromadex as a reliable source of scientifically supported nutraceutical innovations.
Integrating Science and Consumer Wellness
The company’s approach is marked by a detailed understanding of biochemical processes and a commitment to translating this expertise into practical health solutions. With its diversified business segments, Chromadex not only addresses the needs of a broad consumer base but also solidifies its reputation among researchers and industry experts. Its dedicated exploration of key ingredients such as nicotinamide riboside, alongside other innovative compounds, continues to influence the realm of healthy aging and functional nutrition.
ChromaDex Corp. (NASDAQ:CDXC), a company focused on NAD+ and healthy aging science, has announced a significant corporate rebranding initiative. The company will change its name to Niagen Bioscience, Inc. and adopt a new ticker symbol 'NAGE' on the Nasdaq, effective March 19, 2025.
The transition requires no action from current shareholders, and the company's CUSIP number will remain unchanged. ChromaDex plans to release additional information about the name change, rebranding, and future initiatives in a subsequent announcement.
ChromaDex (NASDAQ: CDXC), a leader in NAD+ science and healthy aging, has announced its participation in the 37th Annual ROTH Conference. CEO Rob Fried will be featured on the Longevity and Supplementation Panel on Monday, March 17, at 12:00 PM PT.
The conference will include various engagement formats such as one-on-one meetings, analyst-selected fireside chats, and industry panels. Both CEO Rob Fried and CFO Ozan Pamir will conduct in-person meetings with institutional investors during the event.
The conference will showcase approximately 450 private and public companies across multiple growth sectors, including Healthcare, Technology, Business Services, Consumer, Industrial Growth, Sustainability, and more. The Longevity and Supplementation Panel will be accessible via livestream at wsw.com/webcast/roth50.
ChromaDex (NASDAQ:CDXC) reported strong financial results for Q4 and full year 2024. Fourth quarter highlights include net sales of $29.1 million (up 37% YoY), with Tru Niagen® sales of $22.7 million (up 29% YoY), and net income of $7.2 million.
Full year 2024 performance showed total net sales of $99.6 million (up 19% YoY), gross margin of 61.8%, and net income of $8.6 million. The company generated $12.1 million in operating cash flows and ended the year with $44.7 million in cash and no debt.
Key developments include the launch of Niagen Plus, a pharmaceutical-grade product line available at over 475 U.S. wellness clinics, and receiving FDA Orphan Drug and Rare Pediatric Disease Designations. For 2025, ChromaDex projects approximately 18% year-over-year revenue growth.
ChromaDex (NASDAQ:CDXC), a leader in NAD+ research focusing on healthy aging, has scheduled its Fourth Quarter and Fiscal Year 2024 financial results conference call for March 4, 2025, at 4:30 p.m. ET. The financial results will be released after market close on the same day.
The company will host an investor conference call to discuss Q4 and FY2024 results, providing a general business update. Participants are advised to join 10 minutes before the call using the toll-free number 888.596.4144 with Conference ID 8584242. A webcast replay will be available until March 11, 2025.
ChromaDex Corp. (NASDAQ: CDXC), a leader in NAD+ research and healthy aging science, has announced its participation in the upcoming Lytham Partners 2025 Investor Healthcare Summit. The virtual event will feature a company presentation scheduled for Monday, January 13, 2025, at 12:00 p.m. ET.
Investors can access the webcast directly through Lytham Partners' dedicated event page or the conference homepage. A replay option will be available following the presentation. Additionally, one-on-one investor meetings can be arranged through Lytham representatives or by contacting Ben Shamsian, Vice President at Lytham Partners, who serves as ChromaDex's investor relations contact.
ChromaDex Corp. (NASDAQ:CDXC) has been named to the Inc. 2024 Best in Business list in the Health Products category, recognizing its contributions to the industry through NAD+ research and healthy aging products. The company's portfolio includes Tru Niagen®, a dietary supplement, and the new Niagen IV, both featuring patented nicotinamide riboside (NR), their high-quality NAD+ precursor. This recognition by Inc. magazine acknowledges companies that have achieved significant milestones and demonstrated exceptional execution in their core business.
ChromaDex Corp. (NASDAQ: CDXC) announces that its patented nicotinamide riboside (NR) ingredient, Niagen®, has been selected as the key ingredient in Longevity.Technology's new supplement. Niagen, recognized as the gold standard for NAD+ supplementation, is backed by over 30 peer-reviewed human clinical studies showing benefits in cellular, brain, heart, and muscle health. The company's intellectual property portfolio includes 90+ owned and licensed patents. Niagen is available through business partnerships and is the active ingredient in ChromaDex's Tru Niagen brand, currently the leading healthy-aging NAD+ supplement in the United States.
ChromaDex Corp. (NASDAQ:CDXC) has announced the nationwide rollout of its Niagen® IV products at over 200 Restore Hyper Wellness locations across the United States. Niagen IV, a pharmaceutical-grade nicotinamide riboside chloride (NRC) product, represents an advancement in NAD+ therapy, offering superior benefits compared to traditional NAD+ IV treatments. In clinical studies, Niagen IV demonstrated a 75% shorter infusion time, better tolerability, and achieved a 20% increase in whole blood NAD+ levels three hours post-infusion. The product is compounded and distributed by Wells Pharma of Houston, an FDA-registered 503B facility, and is available exclusively for clinics with medical clearance.
ChromaDex (NASDAQ:CDXC) reported strong Q3 2024 financial results with total net sales of $25.6 million, up 31% year-over-year. The company achieved record net income of $1.9 million ($0.02 per share) and Adjusted EBITDA of $2.9 million. Tru Niagen® sales reached $18.1 million, while Niagen® ingredient sales surged 368% to $6.7 million. Gross margin improved to 63.5%. The company expanded its Niagen+ product line to over 100 wellness clinics and expects approximately 15% revenue growth for full-year 2024.
ChromaDex Corp. (NASDAQ: CDXC) has rescheduled its third quarter 2024 financial results conference call to Thursday, October 31, 2024, at 4:30 p.m. ET. The company, which specializes in NAD+ research and healthy aging, will release its financial results for the quarter ended September 30, 2024, after market close on the same day. The conference call will include management discussion and a general business update. A replay of the call will be available until November 13, 2024.
FAQ
What is the current stock price of Chromadex (CDXC)?
What is the market cap of Chromadex (CDXC)?
What is Chromadex Corp's primary focus?
How does Chromadex generate its revenue?
What makes Chromadex's research unique?
What is the significance of nicotinamide riboside (NR) for Chromadex?
In which segments does Chromadex operate?
How does Chromadex ensure the quality and safety of its products?
How is Chromadex positioned within the competitive landscape?
What are the key benefits of Chromadex's integrated business model?
